Choline treatment affects the liver reticuloendothelial system and plasma fatty acid composition in diabetic rats

Al-Saeedi, Fatma; Cheng, Behling

doi:10.1111/cpf.12027

Cited by 6 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 44 Diabetic rats treated with choline did not decrease plasma fatty acids, suggesting that choline supplementation might not be indicated for serum TG reduction in diabetes. 45 We also showed that FOS was able to significantly reduce cholesterolemia compared to basal values. This effect has been previously reported and explained by an increase in steroids and lipid fecal excretion.…”

Section: Discussionmentioning

confidence: 58%

Choline and Fructooligosaccharide: Non-alcoholic Fatty Liver Disease, Cardiac Fat Deposition, and Oxidative Stress Markers

Haubert¹,

Marchini²,

Cunha³

et al. 2015

Nutr Metab Insights

View full text Add to dashboard Cite

This study investigates the treatment of non-alcoholic fatty liver disease (NAFLD) in rats with choline and fructooligosaccharide (FOS). The healthy control group received standard diet. The other three groups consisted of animals with NAFLD. Group Estr received standard diet; group Echo received standard diet plus choline (3 g/100 g diet); and group Efos received standard diet plus FOS (10 g/100 g diet). Food intake, weight, urinary nitrogen, urinary ammonia, total cholesterol, serum triacylglyceride, liver and heart weights, tissue nitrogen, tissue fat, vitamin E, TBARS, and reduced glutathione (GSH) were measured in hepatic and heart tissue. Choline and FOS treatments resulted in total mean fat reduction in liver and heart tissue of 0.2 and 1.7 g, respectively. Both treatments were equally effective in reducing hepatic and cardiac steatosis. There were no differences in the TBARS level among experimental and control groups, indicating that the proposed treatments had no added protection against free radicals. While all experimental groups had increased vitamin E and GSH levels, choline treatment led to a significant increase compared to control.

show abstract

Section: Discussionmentioning

confidence: 58%

Choline and Fructooligosaccharide: Non-alcoholic Fatty Liver Disease, Cardiac Fat Deposition, and Oxidative Stress Markers

Haubert¹,

Marchini²,

Cunha³

et al. 2015

Nutr Metab Insights

View full text Add to dashboard Cite

show abstract

“…The homogenates were then centrifuged at 11,000 × g for 15 minutes at 4°C, and the supernatant was collected for detecting the values of T-AOC with a commercial kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) following the manufacturer's instructions as described previously. 33 T-AOC was assayed by the reaction of phenanthroline and Fe 2+ . The fluorescence intensity was measured at 520 nm using a spectrophotometer (Hitachi-F-7000; Hitachi).…”

Section: Duodenal T-aoc Determinationmentioning

confidence: 99%

Choline Alleviates Parenteral Nutrition–Associated Duodenal Motility Disorder in Infant Rats

Zhu

Guo

et al. 2015

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

“…This dynamic distribution plays a role in the synthesis of phosphatidylcholine (which makes up nearly half of cell membranes) and in repairing existing damage to hepatic reticuloendothelial function. Consequently, this repair prevents the shift of colloidal choline from the liver to the spleen, increasing liver uptake and reducing splenic uptake (Al-Saeedi & Cheng, 2013;Willyard & Kalathil, 2020). All cells use choline for the biosynthesis of phospholipids (for example, PtdCho) and as a component of phosphatidylcholine to maintain the functions and structural integrity of their cell membranes (Gibellini & Smith, 2010;Liu et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Choline Chloride Encapsulated PLGA Nanoparticles Labelled with Lanthanide Metals

Uçar

2023

EJOSAT

View full text Add to dashboard Cite

Herein, choline chloride was loaded into PLGA nanoparticles to ensure its controlled release. Encapsulation efficiencies (EE) and loading capacities (LC) of them were determined. Also, the produced nanoparticles were analyzed with Zetasizer, FT-IR, SEM, and XRD. The surfaces of the nanoparticles were functionalized by labeling with three different natural lanthanide metals Europium, Gadolinium, and Lutetium to expand diagnostic and therapeutic capabilities with three different imaging tecniques. Metal labeling of the nanoparticles was confirmed with SEM-EDX analysis. EE of the choline chloride nanoparticles were ranging between 62.5%-88.9%. LC of the choline chloride nanoparticles varied from 34.9 to 61.4. The mean size distribution obtained from the Zetasizer analysis of the free nanoparticles was 261.0 ± 7.598 nm. The Z-average size of the encapsulated nanoparticles also varied from 257.5 to 270 nm. The quite negative zeta potential, for example, -17.85 ± 0.165 mV for free NPs showed that the nanoparticles were sufficiently stable. The elemental mapping of the metal labeled NPs verified the labeling procedure. By obtaining therapeutic choline chloride-loaded nanoparticles with different metal labels, theranostic agents with common target and the ability to eliminate limitations with different imaging and detection techniques have been produced.

show abstract

Choline treatment affects the liver reticuloendothelial system and plasma fatty acid composition in diabetic rats

Abstract: Choline treatment affected hepatic reticuloendothelial function and plasma fatty acid composition, but not hepatobiliary function, in diabetic rats. Whether choline treatment is beneficial requires further studies.

Cited by 6 publications

References 28 publications

Choline and Fructooligosaccharide: Non-alcoholic Fatty Liver Disease, Cardiac Fat Deposition, and Oxidative Stress Markers

Choline and Fructooligosaccharide: Non-alcoholic Fatty Liver Disease, Cardiac Fat Deposition, and Oxidative Stress Markers

Choline Alleviates Parenteral Nutrition–Associated Duodenal Motility Disorder in Infant Rats

Choline Chloride Encapsulated PLGA Nanoparticles Labelled with Lanthanide Metals

Contact Info

Product

Resources

About